# A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W

Source: https://onco.cc/trials/nct05552976/  
OnCo record `nct05552976` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Mezigdomide, Carfilzomib, Dexamethasone in multiple myeloma, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) is a phase 3 interventional study registered as NCT05552976 by Bristol-Myers Squibb, with 606 participants enrolled, started 2023-01-10 and due to reach its primary completion in 2026-07-18. Interventions recorded: Mezigdomide, Carfilzomib, Dexamethasone. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05552976
- Phase: 3
- Setting: A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
- Sponsor: Bristol-Myers Squibb
- Enrolled: 606

## Sources

- ClinicalTrials.gov NCT05552976: https://clinicaltrials.gov/study/NCT05552976

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Mezigdomide](https://onco.cc/drugs/mezigdomide/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct05552976.json